liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: Implications for trial design of antiangiogenic antibodies
Show others and affiliations
2002 (English)In: Journal of the National Cancer Institute, ISSN 0027-8874, Vol. 94, no 19, 1484-1493 p.Article in journal (Refereed) Published
Abstract [en]

Background: Vascular endothelial growth factor (VEGF) is a potent angiogenic cytokine, and various inhibitory agents, including specific antibodies, have been developed to block VEGF-stimulated angiogenesis. We developed HuMV833, a humanized version of a mouse monoclonal anti-VEGF antibody (MV833) that has antitumor activity against a number of human tumor xenografts, and investigated the distribution and biologic effects of HuMV833 in patients in a phase I trial. Methods: Twenty patients with progressive solid tumors were treated with various doses of HuMV833 0.3, 1, 3, or 10 mg/kg). Positron emission tomography with 124I-HuMV833 was used to measure the antibody distribution in and clearance from tissues. Magnetic resonance imaging was used to measure the vascular permeability surface area product with a first-pass pharmacokinetic model (Kfp) to determine tumor vascular permeability. Results: The antibody was generally well tolerated, although the incremental dose, phase I study design, and pharmacodynamic end-points could not identify the optimum biologically active dose. Antibody distribution and clearance were markedly heterogeneous between and within patients and between and within individual tumor. HuMV833 distribution to normal tissues also varied among patients, but the antibody was cleared from these tissues in a homogeneous fashion. Permeability was strongly heterogeneous between and within patients and between and within individual tumors. All tumors showed a reduction in kfp 48 hours after the first treatment (median = 44%, range = 4%-91%). Conclusions: Because of the heterogeneity in tumor biology with respect to anti-body uptake and clearance, we suggest that either intrapatient dose escalation approaches or larger, more precisely defined patient cohorts would be preferable to conventional strategies in the design of phase I studies with anitiangiogenic compounds like HuMV833.

Place, publisher, year, edition, pages
2002. Vol. 94, no 19, 1484-1493 p.
National Category
Medical and Health Sciences
URN: urn:nbn:se:liu:diva-25098Local ID: 9530OAI: diva2:245424
Available from: 2009-10-07 Created: 2009-10-07 Last updated: 2011-01-13

Open Access in DiVA

No full text

By organisation
Faculty of Health SciencesOncologyDepartment of Oncology UHL
In the same journal
Journal of the National Cancer Institute
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Total: 25 hits
ReferencesLink to record
Permanent link

Direct link